Frontiers in Immunology (Sep 2021)

Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease

  • Jieqiong Li,
  • Zheng Liu,
  • Panpan Zhang,
  • Wei Lin,
  • Hui Lu,
  • Yu Peng,
  • Linyi Peng,
  • Jiaxin Zhou,
  • Mu Wang,
  • Hua Chen,
  • Lidan Zhao,
  • Li Wang,
  • Chenman Qin,
  • Chaojun Hu,
  • Xiaofeng Zeng,
  • Yan Zhao,
  • Yunyun Fei,
  • Wen Zhang

DOI
https://doi.org/10.3389/fimmu.2021.747076
Journal volume & issue
Vol. 12

Abstract

Read online

ObjectivesTo elucidate heterogeneity of IgG4-related disease (IgG4-RD) based on B cell immunophenotyping.MethodsImmunophenotyping of 4 B-cell subsets in peripheral blood from patients with active IgG4-RD (aIgG4-RD, n=105) was performed using flow cytometry to get preliminary B-cell heterogeneity spectrum. Then 10 B-cell subsets were characterized in aIgG4-RD (n = 49), remissive IgG4-RD (rIgG4-RD, n = 49), and healthy controls (HCs, n = 47), followed by principal components analysis (PCA) and cluster analysis to distinguish B-cell immunophenotypes and classify IgG4-RD patients into subgroups.ResultsCluster analysis identified two endotypes in 105 aIgG4-RD patients based on 4 B-cell subsets: Group1 with higher Breg and naive B cells (n = 48), and Group2 with higher plasmablasts and memory B cells (MBCs) (n = 57). PCA indicated that aIgG4-RD consisted of plasmablast-naive B cell and MBCs-Breg axes abnormalities. There was a negative relationship between naive B cells and disease activity. Both plasmablasts and MBCs were positively associated with serological biomarkers. Cluster analysis stratified aIgG4-RD patients into 3 subgroups based on 10 B-cell subsets: subgroup1 with low MBCs and normal Breg, subgroup2 with high MBCs and low Breg, and subgroup3 with high plasmablasts and low naive B cells. Patients in subroup2 and subgroup3 were more likely to be resistant to treatment.ConclusionPatients with aIgG4-RD can be divided into 3 subgroups based on B cell heterogeneity. The B cell immunophenotyping could help elucidate the pathogenesis of IgG4-RD, identify patients with potential refractory IgG4-RD, and provide important information for the development of new therapies.

Keywords